Immune Checkpoint Inhibitors: all 7,817 studies that test it

Page 48 of 79. Open to participants first (2,632), then studies with results posted, then the rest; newest registration first within each.

• A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated LiposarcomaActive, not recruitingNCT05886634Phase 2
• Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+TWithdrawnNCT05886257Phase 2
• Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT05883644Phase 3
• Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)CompletedNCT05882734Phase 1/2
• Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung CancerActive, not recruitingNCT05882513Phase 2
• PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal CancerCompletedNCT05880082Phase 2
• A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3Active, not recruitingNCT05879978Phase 1
• A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor NaiveTerminatedNCT05879822Phase 2
• Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERASWithdrawnNCT05879484Phase 1/2
• Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent GlioblastomaWithdrawnNCT05879120Phase 2
• A Study of PM8002 in Combination With Chemotherapy in Patients With SCLCActive, not recruitingNCT05879068Phase 2
• A Study of PM8002 in Combination With Chemotherapy in Patients With NENActive, not recruitingNCT05879055Phase 2
• A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.Active, not recruitingNCT05878691Phase 1
• Deep sequencIng in Cutaneous Squamous CEll caRciNomasActive, not recruitingNCT05878288Phase 2
• A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCCCompletedNCT05877820Phase 2
• The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver MetastasesStatus unknownNCT05877001Phase 2
• Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous CarcinomaActive, not recruitingNCT05870761Phase 2
• Study of ZGGS15 in Patients With Advanced Solid TumorsCompletedNCT05864573Phase 1
• Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed GlioblastomaActive, not recruitingNCT05864534Phase 2
• A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsCompletedNCT05864144Phase 1/2
• PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular CarcinomaCompletedNCT05864105Phase 2
• A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced MalignanciesTerminatedNCT05861947Phase 1
• Safety, PK and Efficacy of AI-061 in Advanced Solid TumorsCompletedNCT05858736Phase 1
• Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)Active, not recruitingNCT05856695Phase 2
• A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast CancerActive, not recruitingNCT05852691Phase 2
• The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)TerminatedNCT05849246Phase 2
• A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C MutationsWithdrawnNCT05848843Phase 1
• A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate CancerCompletedNCT05848011Phase 2
• A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal CancerActive, not recruitingNCT05846867Phase 1/2
• Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi SarcomaWithdrawnNCT05846724Phase 2
• A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal AdenocarcinomaActive, not recruitingNCT05846516Phase 1
• A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)Active, not recruitingNCT05845814Phase 1/2
• Efficacy and Safety of Tirelizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Lymph Node Positive Gastric Cancer After SurgeryStatus unknownNCT05844371Phase 2
• A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLCActive, not recruitingNCT05844150Phase 2
• IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder CancerActive, not recruitingNCT05843448Phase 1
• Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung CancerWithdrawnNCT05840770Phase 2
• AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung CancerActive, not recruitingNCT05840016Phase 3
• Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal CancerStatus unknownNCT05839470Phase 2
• Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) CancerActive, not recruitingNCT05836584Phase 2
• Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell CarcinomaTerminatedNCT05834543Phase 1/2
• NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKingActive, not recruitingNCT05825625Phase 2
• A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid TumorsCompletedNCT05824663Phase 1
• Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial CancerActive, not recruitingNCT05824481Phase 2
• Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical CancerActive, not recruitingNCT05824468Phase 2
• Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial CarcinomaStatus unknownNCT05823246Phase 2
• Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)Active, not recruitingNCT05822752Phase 2
• A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid TumorsTerminatedNCT05821777Phase 1/2
• Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.Status unknownNCT05821192Not applicable
• Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT05816499Phase 1/2
• Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT05813626Phase 2
• Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast CancerWithdrawnNCT05809895Phase 2
• A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell CarcinomaActive, not recruitingNCT05808608Phase 1/2
• Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.CompletedNCT05807776Phase 2
• Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCCCompletedNCT05807542Phase 2
• NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHNCompletedNCT05802290Phase 3
• Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal MetastasisActive, not recruitingNCT05802056Phase 1
• A Phase I Study of QL1604 for Advanced Solid TumorsStatus unknownNCT05801094Phase 1
• A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung CancerActive, not recruitingNCT05800015Phase 2/3
• Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal CancerStatus unknownNCT05799443Phase 2
• A SHR-1210 BE Study on Healthy SubjectsTerminatedNCT05799183Phase 1
• Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLCActive, not recruitingNCT05798663Phase 2
• Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic RadiotherapyActive, not recruitingNCT05796089Phase 2
• Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric CancerActive, not recruitingNCT05795296Phase 2
• Foundation and Clinical About the Expression of PD-1 in Peripheral Blood T LymphocytesCompletedNCT05792995Phase 2
• Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal CancerCompletedNCT05792735Phase 2
• Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.WithdrawnNCT05791097Phase 3
• A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid TumorsActive, not recruitingNCT05789069Phase 1
• A Study of CDX-585 in Patients With Advanced MalignanciesCompletedNCT05788484Phase 1
• A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC PatientsActive, not recruitingNCT05787613Phase 2
• A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT05785767Phase 2/3
• Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT05784012Phase 1/2
• Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic MelanomaStatus unknownNCT05783882Phase 3
• POTENT - Tepotinib in Combination With Pembrolizumab in NSCLCActive, not recruitingNCT05782361Phase 1
• Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & ChemotherapyActive, not recruitingNCT05781308Phase 2
• Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal CarcinomaStatus unknownNCT05777707Phase 1/2
• Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)CompletedNCT05775796Phase 2
• Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerActive, not recruitingNCT05775159Phase 2
• A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCCCompletedNCT05773105Phase 1/2
• Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)Active, not recruitingNCT05771480Phase 3
• Study of RO7515629 in Participants With HLA-G Positive Solid TumorsTerminatedNCT05769959Phase 1
• BAT7104 Injection in Patients With Advanced Malignant Tumors.CompletedNCT05767060Phase 1
• Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLCActive, not recruitingNCT05765825Phase 2
• Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRTStatus unknownNCT05763927Phase 2
• A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid TumorsCompletedNCT05763004Phase 1
• Neo-adjuvant Pembrolizumab in Vulvar Squamous Cell Carcinoma: a Clinical Proof-of-concept StudyStatus unknownNCT05761132Phase 2
• Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+TStatus unknownNCT05760599Phase 2
• Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell CarcinomaStatus unknownNCT05759312Phase 1/2
• Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC PatientsCompletedNCT05758116Phase 2
• Using Circulating Tumor DNA to Personalize Duration of Consolidation DurvalumabWithdrawnNCT05757843Phase 2
• Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid TumorsTerminatedNCT05757492Phase 1
• A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLCActive, not recruitingNCT05756972Phase 2
• A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin MelanomaActive, not recruitingNCT05751928Phase 3
• A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal CarcinomaCompletedNCT05751486Phase 1
• Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC PatientsActive, not recruitingNCT05751187Phase 2
• Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.Status unknownNCT05749575Phase 2
• A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell CarcinomaStatus unknownNCT05749042Phase 2
• Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated GlioblastomaActive, not recruitingNCT05743595Phase 1
• Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHNWithdrawnNCT05743270Phase 2
• A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT05741021Phase 2
• Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid TumorsStatus unknownNCT05740215Phase 1/2

← Immune Checkpoint Inhibitors overview